Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Medpace (MEDP) PT Raised to $35.50 at Jefferies; Reiterates Hold
February 28, 2017 9:26 AM ESTJefferies raised its price target on Medpace (NASDAQ: MEDP) to $35.50 (from $34.00) while maintaining a Hold rating. Guidance targets revenue growth of ~7.5% (~8% CC), below consensus' 11.4%. Yet, guidance does bracket Net Income and EPS estimates.
Analyst David Windley commented, "Medpace boasts eye-popping margin,... More
